Los Angeles Capital Management LLC Sells 53,030 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Los Angeles Capital Management LLC lowered its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 13.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 342,992 shares of the company’s stock after selling 53,030 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Organogenesis were worth $1,403,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Capital Square LLC lifted its position in Organogenesis by 23.8% during the 4th quarter. Capital Square LLC now owns 20,450 shares of the company’s stock valued at $84,000 after purchasing an additional 3,930 shares during the period. SG Americas Securities LLC increased its holdings in Organogenesis by 23.2% in the fourth quarter. SG Americas Securities LLC now owns 35,774 shares of the company’s stock valued at $146,000 after purchasing an additional 6,727 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Organogenesis by 1.5% during the third quarter. Bank of New York Mellon Corp now owns 495,729 shares of the company’s stock worth $1,576,000 after buying an additional 7,432 shares during the last quarter. Principal Financial Group Inc. bought a new position in Organogenesis during the third quarter worth about $32,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Organogenesis in the 4th quarter valued at about $43,000. Institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Performance

ORGO opened at $2.44 on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.80 and a quick ratio of 2.44. The company has a market capitalization of $321.98 million, a price-to-earnings ratio of 61.02 and a beta of 1.60. The business’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $3.09. Organogenesis Holdings Inc. has a 1 year low of $1.96 and a 1 year high of $4.70.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $5.00 target price on shares of Organogenesis in a report on Friday, March 1st.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.